Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label trial of subcutaneous efgartigimod PH20 in adult primary immune thrombocytopenia
2020-004033-20Phase 3Active
- Sponsor
- argenx
- Start
- Apr 2021
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of efgartigimod alfa in immune thrombocytopenia (ITP), sponsored by argenx. Primary endpoint: Incidence, frequency, and severity of adverse events. Started Apr 2021; status: active.
02
Drugs
efgartigimod alfa
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on 2020-004033-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004033-20.